Senti Biosciences Holdings (SNTI) Gains from Investment Securities (2022 - 2024)
Senti Biosciences Holdings (SNTI) posted quarterly Gains from Investment Securities of -$20000.0 for Q4 2024, up 86.49% quarter-over-quarter from -$148000.0 in Q2 2023.
Senti Biosciences Holdings (SNTI) Gains from Investment Securities (2022 - 2024) Analysis & Trends
Senti Biosciences Holdings' Gains from Investment Securities history runs 3 years deep, the most recent figure standing at -$20000.0 for Q4 2024.
- In Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$20000.0; the TTM figure through Dec 2024 stood at -$20000.0 (up 90.34% YoY), while the FY2024 annual figure was -$20000.0, up 90.34% from the prior year.
- Gains from Investment Securities for Q4 2024 stood at -$20000.0, up from -$148000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $99000.0 in Q3 2022, with the low at -$8.9 million in Q2 2022.
- The 3-year median for Gains from Investment Securities is -$103500.0 (2023), against an average of -$1.6 million.
- Peak annual rise in Gains from Investment Securities reached 98.33% in 2023, while the deepest fall reached 98.33% in 2023.
- Senti Biosciences Holdings' Gains from Investment Securities stood at -$721000.0 in 2022, then surged by 79.47% to -$148000.0 in 2023, then jumped by 86.49% to -$20000.0 in 2024.
- Business Quant data shows SNTI's Gains from Investment Securities at -$20000.0 in Q4 2024, -$148000.0 in Q2 2023, and -$59000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -20,000.00 |
| Dec 31, 2024 | -20,000.00 |
| Jun 30, 2023 | -148,000.00 |
| Jun 30, 2023 | -148,000.00 |
| Mar 31, 2023 | -59,000.00 |
| Mar 31, 2023 | -59,000.00 |
| Dec 31, 2022 | -721,000.00 |
| Dec 31, 2022 | -721,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | -8.88 Mn |
| Jun 30, 2022 | -8.88 Mn |